Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 10/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166947 | 0.88 | TRPV4 (0.40) | ARPGRSNCACYP11B1CYP11B2 | |
| SCHEMBL2649221 | 0.83 | GABRA1 (0.35) | ARPGRSNCACYP11B1CYP11B2 | |
| SCHEMBL2649122 | 0.83 | GABRA1 (0.39) | ARPGRSNCA | |
| SCHEMBL2413501 | 0.82 | VCAM1 (0.39) | ARSNCATRPV4 | |
| SCHEMBL2648749 | 0.81 | GABRA1 (0.40) | — | |
| SCHEMBL2659509 | 0.81 | GABRA1 (0.36) | — | |
| SCHEMBL2411835 | 0.81 | AR (0.35) | ARSNCACYP11B1CYP11B2 | |
| SCHEMBL30375876 | 0.80 | LPL (0.47) | ARPGRPLA2G7 | |
| SCHEMBL1514603 | 0.80 | LPL (0.47) | ARPGRPLA2G7 | |
| SCHEMBL16734840 | 0.80 | ALDH1A1 (0.45) | ARPGRSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279580-B2 | Imidazo-pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| EP-1511747-B1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2005-07-28 | — | — | US | disclosed |
| EP-1511747-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099816-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165048-A1 | Imidazo-pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | AR 2303/4885PGR 978/4885PLA2G7 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.